Terms: = Ovarian cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
137 results:
1. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
2. Linear IgA bullous dermatosis associated with immunotherapy.
Momin B; Nguyen TF; Glade D; Messer A
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
[TBL] [Abstract] [Full Text] [Related]
3. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
4. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Chen S; Li X; Ao W
BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
[TBL] [Abstract] [Full Text] [Related]
6. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
7. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function.
Funauchi M; Serada S; Hiramatsu K; Funajima E; Kanda M; Nagase Y; Nakagawa S; Ohkawara T; Fujimoto M; Suzuki Y; Ueda Y; Kimura T; Naka T
Int J Cancer; 2024 Feb; 154(3):425-433. PubMed ID: 37728485
[TBL] [Abstract] [Full Text] [Related]
8. Scoulerine promotes cytotoxicity and attenuates stemness in ovarian cancer by targeting PI3K/AKT/mTOR axis.
Wang F; Zhang Y; Pang R; Shi S; Wang R
Acta Pharm; 2023 Sep; 73(3):475-488. PubMed ID: 37708956
[TBL] [Abstract] [Full Text] [Related]
9. Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer.
Zhao L; Chen X; Wu H; He Q; Ding L; Yang B
Biochem Pharmacol; 2023 Sep; 215():115724. PubMed ID: 37524205
[TBL] [Abstract] [Full Text] [Related]
10. Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer.
Habel A; Weili X; Hadj Ahmed M; Stayoussef M; Bouaziz H; Ayadi M; Mezlini A; Larbi A; Yaacoubi-Loueslati B
Int J Biol Markers; 2023 Dec; 38(3-4):203-213. PubMed ID: 37518940
[TBL] [Abstract] [Full Text] [Related]
11. Genetically engineered neural stem cells expressing cytosine deaminase and interferon-beta enhanced T cell-mediated antitumor immunity against gastric cancer in a humanized mouse model.
Choi Y; Lee HK; Ahn D; Nam MW; Go RE; Choi KC
Life Sci; 2023 Sep; 328():121866. PubMed ID: 37331506
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy with IL12 and PD1/ctla4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.
Pavicic PG; Rayman PA; Swaidani S; Rupani A; Makarov V; Tannenbaum CS; Edwards RP; Vlad AM; Diaz-Montero CM; Mahdi H
Oncoimmunology; 2023; 12(1):2198185. PubMed ID: 37066116
[TBL] [Abstract] [Full Text] [Related]
13. Application of Immune Checkpoint Inhibitors in Gynecological cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract] [Full Text] [Related]
14. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract] [Full Text] [Related]
15. Primary leiomyosarcoma of ovary: A rare malignancy as an incidental finding.
Raychaudhuri S; Sidam D; Jain M; Chawla R; Pujani M; Wadhwa R
Indian J Pathol Microbiol; 2022; 65(4):938-941. PubMed ID: 36308213
[TBL] [Abstract] [Full Text] [Related]
16. Construction of Metabolic Molecular Classification and Immune Characteristics for the Prognosis Prediction of ovarian cancer.
Wang K; He H; Feng X
J Immunol Res; 2022; 2022():2359349. PubMed ID: 35800989
[TBL] [Abstract] [Full Text] [Related]
17. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of the Concentration of Selected Elements in Patients with cancer of the Reproductive Organs with Respect to treatment Stage-Preliminary Study.
Wieder-Huszla S; Chudecka-Głaz A; Cymbaluk-Płoska A; Karakiewicz B; Bosiacki M; Chlubek D; Jurczak A
Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745098
[TBL] [Abstract] [Full Text] [Related]
19. treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Sia TY; Manning-Geist B; Gordhandas S; Murali R; Marra A; Liu YL; Friedman CF; Hollmann TJ; Zivanovic O; Chi DS; Weigelt B; Konner JA; Zamarin D
Int J Gynecol Cancer; 2022 Aug; 32(8):1017-1024. PubMed ID: 35545291
[TBL] [Abstract] [Full Text] [Related]
20. Complications after advanced ovarian cancer surgery-A population-based cohort study.
Palmqvist C; Michaëlsson H; Staf C; Johansson M; Albertsson P; Dahm-Kähler P
Acta Obstet Gynecol Scand; 2022 Jul; 101(7):747-757. PubMed ID: 35403699
[TBL] [Abstract] [Full Text] [Related]
[Next]